+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

Mpox Vaccine Market Outlook 2026-2034

  • PDF Icon

    Report

  • 160 Pages
  • November 2026
  • Region: Global
  • OG Analysis
  • ID: 6291295
The Mpox (Monkeypox) Vaccine Market is estimated at USD 141.0 million in 2026 and is projected to reach USD 514.0 million by 2034, growing at a CAGR of 17.5% during 2026-2034.

Market Overview

Mpox vaccines are product-specific preventive vaccines and separately assessed investigational programs, with availability determined by national authorization. Public-health preparedness supports demand for specifically authorized mpox vaccines. Vaccine platforms and delivery requirements differ by product.

Availability and national eligibility affect procurement. Reliable manufacturing and distribution support access. Outbreak conditions and national recommendations shape purchasing. Product positioning depends on appropriate clinical evidence, local authorization and formulation availability, with access conditions differing between healthcare systems. Procurement and prescribing involve different stakeholders. Manufacturers, distributors, clinicians and payers influence availability without performing interchangeable roles in the value chain. Supply decisions require documented quality and dependable distribution. Manufacturing capability, product-specific authorization and finished-dose availability represent distinct qualification considerations. Payer and pharmacy requirements shape practical purchasing. Packaging, replenishment and supply continuity can influence procurement alongside the pharmaceutical product itself. Commercial demand reflects the number of eligible treated patients, continuity of access and the medicines selected within established care pathways.

Key Takeaways

  • Demand drivers: Public-health preparedness supports demand for specifically authorized mpox vaccines. Disease prevalence alone does not establish the revenue available to any particular medicine or supplier. Commercial demand reflects the number of eligible treated patients, continuity of access and the medicines selected within established care pathways.
  • Technology and performance: Vaccine platforms and delivery requirements differ by product. Products within the same therapeutic area should not be treated as clinically interchangeable. Purchasing analysis separates originator and alternative products, where available, and considers how national access arrangements influence realized demand.
  • Challenges and economics: Availability and national eligibility affect procurement. Coverage, dispensing channels and reliable supply also influence whether appropriate treatment reaches eligible patients over time. Product development is evaluated separately from medicines already available through authorized channels.
  • Commercial opportunities: Reliable manufacturing and distribution support access. Commercial opportunity depends on evidence and permitted uses. Formulation development and access initiatives require evaluation within the relevant national treatment and purchasing environment.
  • Geographic considerations: Outbreak conditions and national recommendations shape purchasing. Reimbursement, prescribing and distribution conditions can differ substantially between countries. International availability cannot be inferred solely from a product being marketed elsewhere.
  • Application requirements: Mpox vaccines are product-specific preventive vaccines and separately assessed investigational programs, with availability determined by national authorization. Procurement and prescribing involve different stakeholders. Manufacturers, distributors, clinicians and payers influence availability without performing interchangeable roles in the value chain.
  • Quality and qualification: Supply decisions require documented quality and dependable distribution. Manufacturing capability, product-specific authorization and finished-dose availability represent distinct qualification considerations. Vaccine platforms and delivery requirements differ by product.
  • Purchasing and delivery: Buyers separate authorized products from research candidates. Payer and pharmacy requirements shape practical purchasing. Packaging, replenishment and supply continuity can influence procurement alongside the pharmaceutical product itself.
  • Competitive positioning: Bavarian Nordic, KM Biologics and Emergent BioSolutions are among the companies covered. The analysis distinguishes relevant product, technology and channel roles, with emphasis on application fit, supply capabilities and customer support.
  • Outlook priorities: The mpox (monkeypox) vaccine outlook depends on the interaction of end-use demand, product qualification and commercially viable delivery. Reliable manufacturing and distribution support access. Outbreak conditions and national recommendations shape purchasing.

Competitive Landscape

Verified coverage includes Bavarian Nordic, KM Biologics, Emergent BioSolutions, Moderna, BioNTech, Tonix and GeoVax. The first group provides relevant authorized vaccine references with national differences; Moderna and BioNTech represent investigational mRNA programs, Tonix a preclinical program and GeoVax an investigational MVA program. This seven-company set is a documented exception to the ten-company target. Adding unrelated vaccine manufacturers would misrepresent the narrow market. Comparison evaluates actual product status, supply and evidence, without implying equivalent authorization or availability. Development programs and broader smallpox preparedness contracts require separate revenue boundaries from marketed mpox vaccines.

Companies Mentioned

  • Bavarian Nordic
  • KM Biologics
  • Emergent BioSolutions
  • Moderna (investigational mpox vaccine)
  • BioNTech (investigational mpox vaccine)
  • Tonix Pharmaceuticals (preclinical vaccine)
  • GeoVax (investigational vaccine)

Mpox (Monkeypox) Vaccine Market Analytics

The report employs rigorous tools, including Porter’s Five Forces, value chain mapping, and scenario-based modelling, to assess supply-demand dynamics. Cross-sector influences from parent, derived, and substitute markets are evaluated to identify risks and opportunities. Trade and pricing analytics provide an up-to-date view of international flows, including leading exporters, importers, and regional price trends.

Macroeconomic indicators, policy frameworks such as carbon pricing and energy security strategies, and evolving consumer behaviour are considered in forecasting scenarios. Recent deal flows, partnerships, and technology innovations are incorporated to assess their impact on future market performance.

Mpox (Monkeypox) Vaccine Market Competitive Intelligence

The competitive landscape is mapped through proprietary frameworks, profiling leading companies with details on business models, product portfolios, financial performance, and strategic initiatives. Key developments such as mergers & acquisitions, technology collaborations, investment inflows, and regional expansions are analysed for their competitive impact. The report also identifies emerging players and innovative startups contributing to market disruption.

Regional insights highlight the most promising investment destinations, regulatory landscapes, and evolving partnerships across the report’s covered markets.

Countries Covered

  • North America - Mpox (Monkeypox) Vaccine Market data and outlook to 2034
    • United States
    • Canada
    • Mexico

  • Europe - Mpox (Monkeypox) Vaccine Market data and outlook to 2034
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • BeNeLux
    • Russia
    • Sweden

  • Asia-Pacific - Mpox (Monkeypox) Vaccine Market data and outlook to 2034
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Malaysia
    • Vietnam

  • Middle East and Africa - Mpox (Monkeypox) Vaccine Market data and outlook to 2034
    • Saudi Arabia
    • South Africa
    • Iran
    • UAE
    • Egypt

  • South and Central America - Mpox (Monkeypox) Vaccine Market data and outlook to 2034
    • Brazil
    • Argentina
    • Chile
    • Peru
* We can include data and analysis of additional countries on demand.

Research Methodology

This study combines primary inputs from industry experts across the Mpox (Monkeypox) Vaccine value chain with secondary data from associations, government publications, trade databases, and company disclosures. Proprietary modeling techniques, including data triangulation, statistical correlation, and scenario planning, are applied to deliver reliable market sizing and forecasting.

Key Questions Addressed

  • What are the current market size and outlook across the covered markets?
  • Which product and customer categories offer the most relevant opportunities?
  • How do supply conditions, pricing and competitive strategies affect market development?
  • Which risks and practical investment considerations should decision makers evaluate?

Your Key Takeaways from the Mpox (Monkeypox) Vaccine Market Report

  • Global Mpox (Monkeypox) Vaccine Market size and growth projections (CAGR), 2026-2034
  • Impact of geopolitical developments on Mpox (Monkeypox) Vaccine trade, costs, and supply chains
  • Mpox (Monkeypox) Vaccine Market size, share, and outlook across the 5 regions and country/subregional markets listed above, 2026-2034
  • Mpox (Monkeypox) Vaccine Market size, CAGR, and market share of key products, applications, and end-user verticals, 2026-2034
  • Short- and long-term Mpox (Monkeypox) Vaccine Market trends, drivers, restraints, and opportunities
  • Porter’s Five Forces analysis, technological developments, and Mpox (Monkeypox) Vaccine supply chain analysis
  • Mpox (Monkeypox) Vaccine trade analysis, Mpox (Monkeypox) Vaccine Market price analysis, and Mpox (Monkeypox) Vaccine supply/demand dynamics
  • Company profiles covering business overview, key strategies, financial information where available, and relevant products
  • Latest Mpox (Monkeypox) Vaccine Market news and developments

This product will be delivered within 1-3 business days.

Table of Contents

1. Table of Contents
1.1 List of Tables
1.2 List of Figures
2. Global Mpox (Monkeypox) Vaccine Market Summary, 2026
2.1 Mpox (Monkeypox) Vaccine Industry Overview
2.1.1 Global Mpox (Monkeypox) Vaccine Market Revenues (In US$ billion)
2.2 Mpox (Monkeypox) Vaccine Market Scope
2.3 Research Methodology
3. Mpox (Monkeypox) Vaccine Market Insights, 2025-2035
3.1 Mpox (Monkeypox) Vaccine Market Drivers
3.2 Mpox (Monkeypox) Vaccine Market Restraints
3.3 Mpox (Monkeypox) Vaccine Market Opportunities
3.4 Mpox (Monkeypox) Vaccine Market Challenges
3.5 Tariff Impact on Global Mpox (Monkeypox) Vaccine Supply Chain Patterns
4. Mpox (Monkeypox) Vaccine Market Analytics
4.1 Mpox (Monkeypox) Vaccine Market Size and Share, Key Product, 2026 Vs 2035
4.2 Mpox (Monkeypox) Vaccine Market Size and Share, Dominant Application, 2026 Vs 2035
4.3 Mpox (Monkeypox) Vaccine Market Size and Share, Leading Sales Channel, 2026 Vs 2035
4.4 Mpox (Monkeypox) Vaccine Market Size and Share, High Growth Countries, 2026 Vs 2035
4.5 Five Forces Analysis for Global Mpox (Monkeypox) Vaccine Market
4.5.1 Mpox (Monkeypox) Vaccine Industry Attractiveness Index, 2026
4.5.2 Mpox (Monkeypox) Vaccine Supplier Intelligence
4.5.3 Mpox (Monkeypox) Vaccine Buyer Intelligence
4.5.4 Mpox (Monkeypox) Vaccine Competition Intelligence
4.5.5 Mpox (Monkeypox) Vaccine Product Alternatives and Substitutes Intelligence
4.5.6 Mpox (Monkeypox) Vaccine Market Entry Intelligence
5. Global Mpox (Monkeypox) Vaccine Market Statistics - Industry Revenue, Market Share, Growth Trends and Forecast by segments, to 2035
5.1 World Mpox (Monkeypox) Vaccine Market Size, Potential and Growth Outlook, 2025-2035
5.1 Global Mpox (Monkeypox) Vaccine Sales Outlook and CAGR Growth By Product, 2025-2035
5.2 Global Mpox (Monkeypox) Vaccine Sales Outlook and CAGR Growth By Application, 2025-2035
5.3 Global Mpox (Monkeypox) Vaccine Sales Outlook and CAGR Growth By Sales Channel, 2025-2035
5.4 Global Mpox (Monkeypox) Vaccine Market Sales Outlook and Growth by Region, 2025-2035
6. Asia-Pacific Mpox (Monkeypox) Vaccine Industry Statistics - Market Size, Share, Competition and Outlook
6.1 Asia-Pacific Mpox (Monkeypox) Vaccine Market Insights, 2026
6.2 Asia-Pacific Mpox (Monkeypox) Vaccine Market Revenue Forecast By Product, 2025-2035
6.3 Asia-Pacific Mpox (Monkeypox) Vaccine Market Revenue Forecast By Application, 2025-2035
6.4 Asia-Pacific Mpox (Monkeypox) Vaccine Market Revenue Forecast By Sales Channel, 2025-2035
6.5 Asia-Pacific Mpox (Monkeypox) Vaccine Market Revenue Forecast by Country, 2025-2035
6.5.1 China Mpox (Monkeypox) Vaccine Market Size, Opportunities, Growth 2025-2035
6.5.2 India Mpox (Monkeypox) Vaccine Market Size, Opportunities, Growth 2025-2035
6.5.3 Japan Mpox (Monkeypox) Vaccine Market Size, Opportunities, Growth 2025-2035
6.5.4 Australia Mpox (Monkeypox) Vaccine Market Size, Opportunities, Growth 2025-2035
7. Europe Mpox (Monkeypox) Vaccine Market Data, Penetration, and Business Prospects to 2035
7.1 Europe Mpox (Monkeypox) Vaccine Market Key Findings, 2026
7.2 Europe Mpox (Monkeypox) Vaccine Market Size and Percentage Breakdown By Product, 2025-2035
7.3 Europe Mpox (Monkeypox) Vaccine Market Size and Percentage Breakdown By Application, 2025-2035
7.4 Europe Mpox (Monkeypox) Vaccine Market Size and Percentage Breakdown By Sales Channel, 2025-2035
7.5 Europe Mpox (Monkeypox) Vaccine Market Size and Percentage Breakdown by Country, 2025-2035
7.5.1 Germany Mpox (Monkeypox) Vaccine Market Size, Trends, Growth Outlook to 2035
7.5.2 United Kingdom Mpox (Monkeypox) Vaccine Market Size, Trends, Growth Outlook to 2035
7.5.2 France Mpox (Monkeypox) Vaccine Market Size, Trends, Growth Outlook to 2035
7.5.2 Italy Mpox (Monkeypox) Vaccine Market Size, Trends, Growth Outlook to 2035
7.5.2 Spain Mpox (Monkeypox) Vaccine Market Size, Trends, Growth Outlook to 2035
8. North America Mpox (Monkeypox) Vaccine Market Size, Growth Trends, and Future Prospects to 2035
8.1 North America Snapshot, 2026
8.2 North America Mpox (Monkeypox) Vaccine Market Analysis and Outlook By Product, 2025-2035
8.3 North America Mpox (Monkeypox) Vaccine Market Analysis and Outlook By Application, 2025-2035
8.4 North America Mpox (Monkeypox) Vaccine Market Analysis and Outlook By Sales Channel, 2025-2035
8.5 North America Mpox (Monkeypox) Vaccine Market Analysis and Outlook by Country, 2025-2035
8.5.1 United States Mpox (Monkeypox) Vaccine Market Size, Share, Growth Trends and Forecast, 2025-2035
8.5.1 Canada Mpox (Monkeypox) Vaccine Market Size, Share, Growth Trends and Forecast, 2025-2035
8.5.1 Mexico Mpox (Monkeypox) Vaccine Market Size, Share, Growth Trends and Forecast, 2025-2035
9. South and Central America Mpox (Monkeypox) Vaccine Market Drivers, Challenges, and Future Prospects
9.1 Latin America Mpox (Monkeypox) Vaccine Market Data, 2026
9.2 Latin America Mpox (Monkeypox) Vaccine Market Future By Product, 2025-2035
9.3 Latin America Mpox (Monkeypox) Vaccine Market Future By Application, 2025-2035
9.4 Latin America Mpox (Monkeypox) Vaccine Market Future By Sales Channel, 2025-2035
9.5 Latin America Mpox (Monkeypox) Vaccine Market Future by Country, 2025-2035
9.5.1 Brazil Mpox (Monkeypox) Vaccine Market Size, Share and Opportunities to 2035
9.5.2 Argentina Mpox (Monkeypox) Vaccine Market Size, Share and Opportunities to 2035
10. Middle East Africa Mpox (Monkeypox) Vaccine Market Outlook and Growth Prospects
10.1 Middle East Africa Overview, 2026
10.2 Middle East Africa Mpox (Monkeypox) Vaccine Market Statistics By Product, 2025-2035
10.3 Middle East Africa Mpox (Monkeypox) Vaccine Market Statistics By Application, 2025-2035
10.4 Middle East Africa Mpox (Monkeypox) Vaccine Market Statistics By Sales Channel, 2025-2035
10.5 Middle East Africa Mpox (Monkeypox) Vaccine Market Statistics by Country, 2025-2035
10.5.1 Middle East Mpox (Monkeypox) Vaccine Market Value, Trends, Growth Forecasts to 2035
10.5.2 Africa Mpox (Monkeypox) Vaccine Market Value, Trends, Growth Forecasts to 2035
11. Mpox (Monkeypox) Vaccine Market Structure and Competitive Landscape
11.1 Key Companies in Mpox (Monkeypox) Vaccine Industry
11.2 Mpox (Monkeypox) Vaccine Business Overview
11.3 Mpox (Monkeypox) Vaccine Product Portfolio Analysis
11.4 Financial Analysis
11.5 SWOT Analysis
12. Appendix
12.1 Global Mpox (Monkeypox) Vaccine Market Volume (Tons)
12.1 Global Mpox (Monkeypox) Vaccine Trade and Price Analysis
12.2 Mpox (Monkeypox) Vaccine Parent Market and Other Relevant Analysis
12.3 Publisher Expertise
12.2 Mpox (Monkeypox) Vaccine Industry Report Sources and Methodology

Companies Mentioned

  • Bavarian Nordic
  • KM Biologics
  • Emergent BioSolutions
  • Moderna (investigational mpox vaccine)
  • BioNTech (investigational mpox vaccine)
  • Tonix Pharmaceuticals (preclinical vaccine)
  • GeoVax (investigational vaccine)

Table Information